| 52.57 Real-Time Quote |  +0.48 / +0.92%Today’s Change | 41.12 Today|||52-Week Range 58.41 | +6.59% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $58.7B |
Company Description
Eli Lilly & Co. discovers, develops, manufactures and sells pharmaceutical products. The company operates through two segments: Human Pharmaceutical Products and Animal health business segment. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health business segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. The company was founded by Colonel Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Employees
Shareholders
| Mutual fund holders | 31.75% |
| Other institutional | 31.33% |
| Individual stakeholders | 12.45% |
Top Executives
| Derica W. Rice, MBA | Chief Executive Officer, CFO & EVP-Global Services |
| Thomas F. Bumol, PhD | Vice President-Biotechnology Discovery Research |
| Timothy J. Garnett, MD | Chief Medical Officer |
| Jan M. Lundberg, PhD | Executive Vice President-Science & Technology |
| Enrique A. Conterno, MBA | Senior Vice President |
.
